SUMMARY This study was designed to determine the effects of colloidal bismuth subcitrate De-Nol on gastric HCO-secretion in 24 healthy subjects and on gastric and duodenal HCO-secretion in dogs with gastric and duodenal fistulae. Alkaline secretion was measured after pretreatment with ranitidine to abolish the H+ secretion using a constant perfusion aspiration system and back titration of the perfusates to the original pH 6.0. Luminal release of PGE2 was also measured in the gastric and duodenal perfusates. Addition of De-Nol in gradually increasing concentrations resulted in step wise increments in gastric HCO-secretion in man and in dogs reaching, respectively, about 80% and 55% of the maximal HCO-response to 16, 16dimethyl-PGE2 (dmPGE2). The duodenal HCO-response to De-Nol in dogs reached 72% of the dmPGE2 maximum. These effects were accompanied by a significant increase in luminal release of PGE2. Pretreatment with atropine reduced basal and in part De-Nol induced alkaline secretion, whereas pirenzepine did not affect this secretion in man and dogs. Aspirin (in man) and indomethacin (in dogs) reduced the release of PGE2 by about 80% and suppressed almost completely the gastric and duodenal HCO-response to De-Nol in these species. This study provides evidence that De-Nol stimulates gastroduodenal alkaline secretion through a prostaglandin dependent mechanism.
nor an antacid, yet it has an impressive efficacy in the prevention of acute gastric lesions in experimental animals4 and in healing of chronic peptic ulcers in man. 5 Because alkaline secretion has been shown to play an important role in mucosal protection, particularly against luminal acid-pepsin aggression,9 in various species, including man, we decided to determine the influence of De-Nol on this secretion from the gastroduodenal mucosa. Alkaline secretion depends, in part, upon mucosal prostaglandins (PG)"" and is under vagal cholinergic control.'2" Thus attempts have been made to evaluate the effects of De-Nol on mucosal production of PG, and further the effects of blockade of cyclooxygenase and muscarinic receptors on De-Nol-induced alkaline secretion in man and in dogs have been examined. 1557 Konitlurek, Bilski, Kwiecien, Obtulowicz, Kopp, and Oleksy
Methods

SUBJ ECTS
The study was approved by the Institutional Ethical Committee and informed consent was obtained from each subject tested.
The study was carried out on 24 male volunteers, 20-25 years (mean 21) , and weighing 58-74 kg (mean weight 71 kg). All subjects were in good health and without gastrointestinal disorder. Gastroduodenoscopy carried out before the start of the study revealed no abnormalities or peptic ulceration.
Several series of experiments were carried out on the same subjects with five to seven days washout between series. The evening before the examination and on the morning of examination, four tablets of ranitidine (1200 mg) (Glaxo, England) were given to completely suppress gastric acid secretion (luminal pH 7-0 or above) and thus prevent any conversion of HCO-into CO2. During the examination, a double lumen gastroduodenal Dreiling tube with endotracheal cuff was inserted and positioned fluoroscopically, the cuff being inflated (with 20 ml water) in the duodenal bulb just beyond the pylorus. This prevented any escape of gastric perfusate into the duodenum and any reflux of the duodenal content into the stomach as described before.'4 A polyethylene catheter attached to the Dreiling tube, with openings in the proximal part of the stomach was used to perfuse the stomach with saline adjusted to pH 6-0, and containing phenol red as a nonabsorbable marker (40 !tg/ml). Another polyethlene catheter attached to the Dreiling tube was filled with agar-KCl and served as a recording electrode for the measurement of the gastric potential difference (PD) in the oxyntic gland area. The potential difference, expressed in millivolts (mV) referred to the polarity of the gastric lumen compared with the venous blood adjusted to zero. The distal portion of the Dreiling tube with wide lateral openings was located in the distal portion of the stomach for the continuous aspiration of the gastric content. The rate of perfusion was 600 ml/h. This perfusion aspiration procedure was carried out throughout the examination. The volume of gastric aspirate was measured and HCO3 contents were determined by back titration of gastric perfusate to the original pH as described before.' The samples of the perfusates were saved for phenol red determination by spectrophotometry at 520 nm and for PGE2 radioimmunoassay using PGE, kits (New England Nuclear, Munich, FRG) as described before. "' 11 "6 In tests undertaken with De-Nol on 12 subjects (group A), gastric perfusion was first carried out with saline for 60 minutes and then De-Nol was added to the perfusate in gradually increasing concentrations (5-20 mg/ml), each concentration being present for 60 minutes then doubled. At the end of the experiment, 16. 16-dimethyl-PGE2 (dmPGE,) was introduced into the stomach in the concentration of 5 [tg/ml which had been shown in other tests to induce maximal HCO-output from the human stomach." In control tests the HCO-output were determined during gastric perfusion with saline without De-Nol for the duration of the experiment.
In a second series of tests done on six subjects (group B), gastric alkaline secretion was measured for a 60 minute period with De-Nol added to the perfusion fluid at a concentration of 20 mg/ml. Ten micrograms per kilograms of atropine or pirenzepine was injected iv the perfusion aspiration procedure being carried out for the next 60 minute period. In control experiments, the response to 20 mg/ml DeNol alone was carried out for the duration of the test (120 min).
Tests with aspirin (ASA) were carried out on six subjects (group C); gastric HCO-response to De-Nol was measured during a 60 minute period with or without (control tests) pretreatment with 20 mg/kg ASA given po given about 60 minutes before the start of the examination.
STUDIES ON ANIMALIS
Six mongrel dogs (16-20 kg) were prepared with gastric fistulae (GF) and duodenal fistulae (DF). The procedure included the ligation of the accessory pancreatic duct and the diversion of bile and pancreatic juice from the duodenum to the upper jejunum by transplantation of the ducts with a piece of surrounding duodenum as described before.'8 One cuff of Dacron mesh was placed around the proximal duodenum just beyond the pylorus and a second was placed around the mid-duodenum just proximal to the cannula of the duodenal fistulae. The cuffs were used to splint the duodenal wall and thus to seal the space between the wall and the inflated balloons of Foley catheter. Two connected Foley catheters were used during the experiment, one with a balloon inflated in the distal portion of the stomach to seal the gastroduodenal junction and another in the mid-duodenum to seal the distal end of the proximal duodenum. The gastric catheter was externalised through the gastric fistulae while the small polyethylene tube attached to it was used to perfuse the stomach. The duodenal catheter was externalised through the duodenal fistulae and used to drain the proximal duodenum between the balloons. A polyvinyl tube attached to the duodenal catheter was used to perfuse the duodenum. The perfused duodenum was about 5 cm long. The perfusion fluid contained a non-absorbable marker, phenol red, at a concentration of 40 p.g/ml.
The whole stomach and the upper duodenum (between balloons) were perfused at a rate of 80 mI/h using saline adjusted to pH 6-0. The perfusates were collected separately by gravity drainage and pooled in 15 minute samples. The volume was measured and the amounts of HCO-in the perfusates were determined by back titration to the original pH 6-0 as in the human studies. The samples of the perfusates were also saved and frozen to -20°C to determine the content of PGE2 using radioimmunoassay.""'
The potential difference of the gastric and duodenal mucosa was also measured using recording electrodes in the form of 80 cm long polyethylene tubes filled with saturated KCI in 4% agar and placed along the Foley catheter in the proximal part of the stomach and in the upper duodenum. The reference electrode was connected to the peripheral vein as described before. '5 Secretory studies started after about four to five weeks after surgery. Food, but not water, was withheld for about 18 hours before each experiment. Ranitidine (20 mg/kg) was injected iv to suppress gastric acid secretion and then both gastric and duodenal perfusions were started and assayed as in human studies.
Gastric and duodenal perfusions were first carried out for 60 minutes to determine basal HCO-secretion in each experiment. In tests with De-Nol, gradually increased concentrations (10-80 mg/ml) were added to the gastric and duodenal perfusion fluids, each concentration being administered for 60 minutes, and then doubled. During the final 60 minute period of the experiment dmPGE, was added to the perfusion fluid at a concentration of 5Rg/ml which has been shown to induce maximal HCO-secretion from the gastroduodenal mucosa in dogs.", In control tests, gastric and duodenal perfusions were done using saline without De-Nol for the duration of the experiment (240 minutes).
In other tests, atropine (25 [tg/kg), pirenzepine (25 sg/kg) or indomethacin (2-5 mg/kg) was injected iv and then De-Nol was added to the gastric and duodenal perfusion fluids in gradually increasing concentrations as described above. In separate tests, basal HCO-secretion was measured for 60 minutes from the stomach and duodenum during their perfusion with saline (without De-Nol) and then atropine, pirenzepine or indomethacin was injected iv in the same doses as above, the perfusion being continued for the next 60 minute period. 
Results
STUI)IES IN MAN
The basal gastric HCO-secretion in 12 healthy subjects of group A was about 1100±260 p.mol/h (mean ± SEM). The values of HCO3 output fluctuated during the observation period within about 30% of the average value. After the addition of DeNol to the perfusion fluid there was a significant increase in HCO-outputs starting with 10 mg/ml. With higher concentrations of De-Nol in the perfusion fluid (20 mg/ml) the HCO-outputs almost doubled and reached about 80% of the maximal response to dmPGE in these subjects (Fig. 1) . In these tests with De-Nol stimulated alkaline secretion, the recovery of the phenol red marker infused into the stomach averaged about 96%. De-Nol (Fig. 2) . Basal PGE2 released into the gastric lumen saline perfusion averaged 118±20 ng/h. Addition of De- Nol at a dose of 10 and 20 mg/ml to the perfusion resulted in a significant increase in luminal release of PGE2 (Fig. 1) . Basal (Fig. 2) . Neither atropine nor pirenzepine influenced basal or De-Nol stimulated luminal release of PGE2 in these tests (Fig. 2) increase in PGE2 contents that were significant at 40 and 80 mg/ml concentrations of De-Nol (Table) . (Table) . Indomethacin (2.5 mg/kg) did not change significantly basal gastric HCO outputs but reduced by about 60% basal duodenal HCO-outputs. Indomethacin almost completely abolished gastric and duodenal HCO-responses to De-Nol (Figs 3 and 4) . Indomethacin reduced by about 75% basal PGE2 release and abolished the PGE2 release induced by De-Nol (Table) .
Discussion
This study provides evidence that De-Nol (colloidal bismuth subcitrate) stimulates gastric and duodenal alkaline secretion and that this depends, at least in part, upon the mucosal generation of prostaglandins.
Previous studies showed that alkaline secretion by gastric and duodenal mucosa is an energy dependent process that is under local humoral control involving mucosal prostaglandin""' and under neural control Gastroduodenal alkaline secretion may also be stimulated by vagal-cholinergic excitation. Vagal stimulation by sham feeding was reported to increase this stimulation,7 ' whereas anticholinergics were found to cause the inhibition of this secretion.7 ' Safsten and Flemstrom2' reported recently that pirenzepine, which is classified as an MI-selective muscarinic antagonist, increased rather than inhibited the duodenal alkaline secretion possibly by acting through the MI receptors in the brain. Thus we compared the influence of atropine and pirenzepine on basal and De-Nol stimulated alkaline secretion in man and dogs. We confirmed that atropine strongly suppressed basal alkaline secretion but had only little influence on the increase of alkaline secretion in response to De-Nol. Pirenzepine did not affect basal or De-Nol induced alkaline secretion from the stomach or duodenum. Neither of the antimuscarinic agents affected mucosal formation of PGE2. We found that atropine strongly reduced basal gastroduodenal alkaline secretion in human subjects and in dogs, whereas pirenzepine did not interfere with that secretion, which indicates that muscarinic receptors are involved in the mechanism of alkaline secretion.
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